Search research articles
Contact Us
Filters
Showing results (21-30 of 136) with videos related to
Page
of 14
Sort By:
Current Opinion in Oncology
|
November 1, 2002
Emerging strategies in tumor vaccines
I Caroline Le Poole, M A Todd Gerberi, W Martin Kast
Methods in Molecular Medicine
|
February 11, 2012
Molecular characterization of melanoma-derived antigens
M Visser, M P Velders, M P Rudolf, et al.
Expert Opinion on Biological Therapy
|
March 5, 2004
Peptide-based vaccines for cancer immunotherapy
Joeli A Brinkman, Steven C Fausch, Jeffrey S Weber, et al.
Journal of Translational Medicine
|
October 25, 2006
Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant
Yi T Koh, Sean A Higgins, Jeffrey S Weber, et al.
Cancers
|
September 9, 2022
Investigation of the Optimal Prime Boost Spacing Regimen for a Cancer Therapeutic Vaccine Targeting Human Papillomavirus
Diane M Da Silva, Emma A Martinez, Lies Bogaert, et al.
International Reviews of Immunology
|
September 10, 2003
CD4+ T cell matters in tumor immunity
Markwin P Velders, Mary A Markiewicz, Gretchen L Eiben, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
October 29, 2014
Functional analysis of HPV-like particle-activated Langerhans cells in vitro
Lisa Yan, Andrew W Woodham, Diane M Da Silva, et al.
Cancer Immunity
|
April 25, 2008
Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines
Maurizio Chiriva-Internati, Everardo Cobos, Diane M Da Silva, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 10, 2002
Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses
Steven C Fausch, Diane M Da Silva, Michael P Rudolf, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 24, 2009
Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16
Laura M Fahey, Adam B Raff, Diane M Da Silva, et al.
Page
of 14
Search research articles
Search
Showing results (21-30 of 136) with videos related to
Sort By:
Page
of 14
Current Opinion in Oncology
|
November 1, 2002
Emerging strategies in tumor vaccines
I Caroline Le Poole, M A Todd Gerberi, W Martin Kast
Methods in Molecular Medicine
|
February 11, 2012
Molecular characterization of melanoma-derived antigens
M Visser, M P Velders, M P Rudolf, et al.
Expert Opinion on Biological Therapy
|
March 5, 2004
Peptide-based vaccines for cancer immunotherapy
Joeli A Brinkman, Steven C Fausch, Jeffrey S Weber, et al.
Journal of Translational Medicine
|
October 25, 2006
Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant
Yi T Koh, Sean A Higgins, Jeffrey S Weber, et al.
Cancers
|
September 9, 2022
Investigation of the Optimal Prime Boost Spacing Regimen for a Cancer Therapeutic Vaccine Targeting Human Papillomavirus
Diane M Da Silva, Emma A Martinez, Lies Bogaert, et al.
International Reviews of Immunology
|
September 10, 2003
CD4+ T cell matters in tumor immunity
Markwin P Velders, Mary A Markiewicz, Gretchen L Eiben, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
October 29, 2014
Functional analysis of HPV-like particle-activated Langerhans cells in vitro
Lisa Yan, Andrew W Woodham, Diane M Da Silva, et al.
Cancer Immunity
|
April 25, 2008
Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines
Maurizio Chiriva-Internati, Everardo Cobos, Diane M Da Silva, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
September 10, 2002
Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses
Steven C Fausch, Diane M Da Silva, Michael P Rudolf, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 24, 2009
Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16
Laura M Fahey, Adam B Raff, Diane M Da Silva, et al.
Page
of 14